The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts

被引:36
作者
Haas, Mark [1 ]
机构
[1] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA
关键词
classification systems: Banff classification; kidney transplantation/nephrology; pathology/histopathology; protocol biopsy; rejection: acute; rejection: antibody-mediated (ABMR); rejection: chronic; translational research/science; DONOR-SPECIFIC ANTIBODIES; POSITIVE CROSS-MATCH; KIDNEY-TRANSPLANT RECIPIENTS; ACUTE HUMORAL REJECTION; NK CELLS; GLOMERULOPATHY; BIOPSIES; PROSPECTS; THERAPY;
D O I
10.1111/ajt.15088
中图分类号
R61 [外科手术学];
学科分类号
摘要
The Banff classification of renal allograft pathology defines specific morphologic lesions that are used in the diagnosis of active (glomerulitis, peritubular capillaritis, endarteritis) and chronic (transplant glomerulopathy, peritubular capillary basement membrane multilayering, transplant arteriopathy) antibody-mediated rejection (ABMR). However, none of these individual lesions are specific for ABMR, and for this reason Banff requires 1 or more additional findings, including C4d deposition in peritubular capillaries, presence of circulating donor-specific antibodies (DSAs), and/or expression in the tissue of transcripts strongly associated with ABMR, for a definitive diagnosis of ABMR to be made. In addition, while animal studies examining serial biopsies have established the progression of morphologic lesions of active to chronic ABMR as well as intermediate forms (chronic active ABMR) exhibiting features of both, clear documentation that lesions of chronic ABMR require the earlier presence of corresponding active and intermediate lesions is less well established in human renal allografts. This review examines temporal relationships between key morphologic lesions of active and chronic ABMR in biopsies of human grafts, likely intermediate forms, and findings for and possibly against direct and potentially interruptible progression from active to chronic lesions.
引用
收藏
页码:2849 / 2856
页数:8
相关论文
共 40 条
[1]   Anti-huCD20 Antibody Therapy for Antibody-Mediated Rejection of Renal Allografts in a Mouse Model [J].
Abe, T. ;
Ishii, D. ;
Gorbacheva, V. ;
Kohei, N. ;
Tsuda, H. ;
Tanaka, T. ;
Dvorina, N. ;
Nonomura, N. ;
Takahara, S. ;
Valujskikh, A. ;
Baldwin, W. M., III ;
Fairchild, R. L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (05) :1192-1204
[2]   Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients [J].
Aubert, Olivier ;
Loupy, Alexandre ;
Hidalgo, Luis ;
van Huyen, Jean-Paul Duong ;
Higgins, Sarah ;
Viglietti, Denis ;
Jouven, Xavier ;
Glotz, Denis ;
Legendre, Christophe ;
Lefaucheur, Carmen ;
Halloran, Philip F. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (06) :1912-1923
[3]   Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients [J].
Bagnasco, Serena M. ;
Zachary, Andrea A. ;
Racusen, Lorraine C. ;
Arend, Lois J. ;
Carter-Monroe, Naima ;
Alachkar, Nada ;
Nazarian, Susanna M. ;
Lonze, Bonnie E. ;
Montgomery, Robert A. ;
Kraus, Edward S. .
TRANSPLANTATION, 2014, 97 (04) :440-445
[4]   Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy [J].
Baid-Agrawal, Seema ;
Farris, Alton B., III ;
Pascual, Manuel ;
Mauiyyedi, Shamila ;
Farrell, Mary Lin ;
Tolkoff-Rubin, Nina ;
Collins, A. Bernard ;
Frei, Ulrich ;
Colvin, Robert B. .
KIDNEY INTERNATIONAL, 2011, 80 (08) :879-885
[5]   Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation [J].
Bailly, Elodie ;
Anglicheau, Dany ;
Blancho, Gilles ;
Gatault, Philippe ;
Vuiblet, Vincent ;
Chatelet, Valerie ;
Morelon, Emmanuel ;
Malvezzi, Paolo ;
Parissiadis, Anne ;
Tourret, Jerome ;
Guidicelli, Gwendaline ;
Sayegh, Johnny ;
Mousson, Christiane ;
Grimbert, Philippe ;
Top, Isabelle ;
Le Quintrec, Moglie ;
Purgus, Raj ;
Westeel, Pierre Francois ;
Proust, Barbara ;
Chabot, Valerie ;
Lebranchu, Yvon ;
Dehaut, Frederic ;
Buchler, Matthias .
TRANSPLANTATION, 2018, 102 (04) :688-698
[6]   Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts [J].
Baldwin, William M., III ;
Valujskikh, Anna ;
Fairchild, Robert L. .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2016, 21 (01) :7-14
[7]   Acute humoral rejection of renal allografts in CCR5-/- recipients [J].
Bickerstaffa, A. ;
Nozaki, T. ;
Wang, J. -J. ;
Pelletier, R. ;
Hadley, G. ;
Nadasdy, G. ;
Nadasdy, T. ;
Fairchild, R. L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (03) :557-566
[8]   Alloantibody Levels and Acute Humoral Rejection Early After Positive Crossmatch Kidney Transplantation [J].
Bums, J. M. ;
Comell, L. D. ;
Perry, D. K. ;
Pollinger, H. S. ;
Gloor, J. M. ;
Kremers, W. K. ;
Gandhi, M. J. ;
Dean, P. G. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (12) :2684-2694
[9]   Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients [J].
Choi, J. ;
Aubert, O. ;
Vo, A. ;
Loupy, A. ;
Haas, M. ;
Puliyanda, D. ;
Kim, I. ;
Louie, S. ;
Kang, A. ;
Peng, A. ;
Kahwaji, J. ;
Reinsmoen, N. ;
Toyoda, M. ;
Jordan, S. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (09) :2381-2389
[10]   Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year [J].
Cornell, L. D. ;
Schinstock, C. A. ;
Gandhi, M. J. ;
Kremers, W. K. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (05) :1293-1302